These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8708595)

  • 21. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial.
    Kilicdag EB; Bagis T; Tarim E; Aslan E; Erkanli S; Simsek E; Haydardedeoglu B; Kuscu E
    Hum Reprod; 2005 Jun; 20(6):1521-8. PubMed ID: 15790610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
    Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH
    Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Metformin in patients with coronary disease?].
    Schneider J
    Internist (Berl); 1995 May; 36(5):522. PubMed ID: 7601626
    [No Abstract]   [Full Text] [Related]  

  • 24. [Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes].
    André P
    Rev Epidemiol Sante Publique; 1999 Mar; 47(1):93-5. PubMed ID: 10214683
    [No Abstract]   [Full Text] [Related]  

  • 25. Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome.
    Carlsen SM; Kjøtrød S; Vanky E; Romundstad P
    Acta Obstet Gynecol Scand; 2007; 86(2):145-50. PubMed ID: 17364275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
    Nass CM; Blumenthal RS
    Am J Manag Care; 2000 Dec; 6(24 Suppl):S1247-56; quiz S1257-8. PubMed ID: 11142005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats.
    Majithiya JB; Balaraman R
    Life Sci; 2006 Apr; 78(22):2615-24. PubMed ID: 16318863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
    von Bibra H; Hansen A; Dounis V; Bystedt T; Malmberg K; Rydén L
    Heart; 2004 Dec; 90(12):1483-4. PubMed ID: 15547039
    [No Abstract]   [Full Text] [Related]  

  • 29. Metformin as a weight-loss tool in "at-risk" obese adolescents: a magic bullet?
    Kasa-Vubu JZ
    J Pediatr; 2008 Jun; 152(6):750-2. PubMed ID: 18492507
    [No Abstract]   [Full Text] [Related]  

  • 30. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
    Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
    Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
    Stambolic V; Woodgett JR; Fantus IG; Pritchard KI; Goodwin PJ
    Breast Cancer Res Treat; 2009 Mar; 114(2):387-9. PubMed ID: 18438706
    [No Abstract]   [Full Text] [Related]  

  • 32. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
    Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
    Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus.
    Wildasin EM; Skaar DJ; Kirchain WR; Hulse M
    Pharmacotherapy; 1997; 17(1):62-73. PubMed ID: 9017766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determining lipid risk factors for coronary heart disease.
    Gelskey DE; Fox JG; Hammond GW
    CMAJ; 1989 Mar; 140(5):493. PubMed ID: 2634969
    [No Abstract]   [Full Text] [Related]  

  • 36. [Dyslipoproteinemias and the circadian variability of the lipid content of the blood in ischemic heart disease].
    Seliverstova GP; Oranskiĭ IE
    Lab Delo; 1983; (1):14-7. PubMed ID: 6185723
    [No Abstract]   [Full Text] [Related]  

  • 37. [Blood lipid spectrum and blood coagulation indices in ischemic heart disease].
    Furkalo NK; Bol'shakova RM; Solovtsova KM
    Vrach Delo; 1981 Jun; (6):29-33. PubMed ID: 7257291
    [No Abstract]   [Full Text] [Related]  

  • 38. It takes more than one CAMERA to study cardiovascular protection by metformin.
    Riksen NP; el Messaoudi S; Rongen GA
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):105-6. PubMed ID: 24622709
    [No Abstract]   [Full Text] [Related]  

  • 39. Metformin for cardiovascular disease: promise still unproven.
    Lexis CP; van der Horst IC
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):94-5. PubMed ID: 24622700
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of intravenous contrast agents in patients receiving metformin.
    Gupta R
    Radiology; 2002 Oct; 225(1):311-2; author reply 312. PubMed ID: 12355024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.